India’s first primitive coronavirus vaccine, developed by Bharat Biotech in collaboration with Indian Council of Medical Research (ICMR) and NIV, is ready. Bharat Biotech is one of the seven Indian firms to work on coronavirus vaccines. The company was the first to be granted with the regulatory nod to start phase 1 and phase 2 human trails. Zydus Cadila has also received the permission from the Drugs Controller General of India (DCGI) for human clinical trails for its homegrown developed vaccine candidates against Sars-COV-2.
ICMR DG Balram Bhargava has written down to Bharat Biotech and principal investigators of medical colleges. He wrote that this is the first indigenous vaccine and is being surveiled by the top level of the Government as it is one of the top most priority projects. The ICMR has recognized 11 clinical trails sites, including medical institutions and hospitals, and has asked their principal investigators to ensure that the subject enrollment is initiated no later than July 7th.
Over seven vaccines are currently bring researched in India with two receiving the nod for human trails. Indian manufacturers account for 60% of vaccine supplies made of UNICEF . In the past years, India has emerged as one of the significant vaccine manufacturing hubs.